News

Roche is suspended from ABPI for “actions likely to bring discredit” on the industry

BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a835 (Published 16 July 2008) Cite this as: BMJ 2008;337:a835
  1. Roger Dobson
  1. 1Abergavenny

    Roche has been suspended from membership of the Association of the British Pharmaceutical Industry (ABPI) for a minimum of six months over serious breaches of the association’s code of practice.

    In particular, the company was held to be in breach of clause 2, which deals with actions likely to bring discredit on, or reduce confidence in, the drug industry.

    The action followed a complaint made by a former Roche employee, Ryta Kuzel, who referred to an article in the Financial Times (www.ft.com, 12 Feb, “Diet pills case sheds light on Roche practice”) that alleged the company had sold large quantities of orlistat (Xenical), a prescription only drug for the treatment of obesity, to the operator of a group of private diet clinics. The …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe